药物发现
毒性
高通量筛选
计算生物学
药品
药物毒性
药理学
化学
生物
生物信息学
有机化学
作者
David C. Murray,Lisa McWilliams,Mark Wigglesworth
出处
期刊:Methods in molecular biology
日期:2016-01-01
卷期号:: 245-262
被引量:6
标识
DOI:10.1007/978-1-4939-3673-1_16
摘要
Understanding compound-driven cell toxicity is vitally important for all drug discovery approaches. With high-throughput screening (HTS) being the key strategy to find hit and lead compounds for drug discovery projects in the pharmaceutical industry [1], an understanding of the cell toxicity profile of hit molecules from HTS activities is fundamentally important. Recently, there has been a resurgence of interest in phenotypic drug discovery and these cell-based assays are now being run in HTS labs on ever increasing numbers of compounds. As the use of cell assays increases the ability to measure toxicity of compounds on a large scale becomes increasingly important to ensure that false hits are not progressed and that compounds do not carry forward a toxic liability that may cause them to fail at later stages of a project. Here we describe methods employed in the AstraZeneca HTS laboratory to carry out very large scale cell toxicity screening.
科研通智能强力驱动
Strongly Powered by AbleSci AI